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Abstract
 
It is now clear that functionally specialized regulatory T (Treg) cells exist as part of the normal
immune repertoire, preventing the development of pathogenic responses to both self- and in-
testinal antigens. Here, we report that the Treg cells that control intestinal inflammation ex-
 
press the same phenotype (CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
) as those that control autoimmunity.
Previous studies have failed to identify how CD25
 
1
 
 Treg cells function in vivo. Our studies re-
veal that the immune-suppressive function of these cells in vivo is dependent on signaling via
the negative regulator of T cell activation cytotoxic T lymphocyte–associated antigen 4
(CTLA-4), as well as secretion of the immune-suppressive cytokine transforming growth factor
 
b
 
. Strikingly, constitutive expression of CTLA-4 among CD4
 
1
 
 cells was restricted primarily to
Treg cells, suggesting that CTLA-4 expression by these cells is involved in their immune-sup-
pressive function. These findings raise the possibility that Treg cell function contributes to the
immune suppression characteristic of CTLA-4 signaling. Identification of costimulatory mole-
cules involved in the function of Treg cells may facilitate further characterization of these cells
and development of new therapeutic strategies for the treatment of inflammatory diseases.
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1
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Introduction
 
The intestine is home to a huge number of resident bacte-
ria, estimated to be in the order 10
 
14
 
/g of tissue. These are
a significant source of both antigens and proinflammatory
molecules present in bacterial cell walls. Despite this poten-
 
tial immune stimulus, it is well recognized that immune
responses in the intestine remain in a state of controlled
inflammation (1). Recently, we have identified a pheno-
typically and functionally distinct population of regulatory
T (Treg) cells capable of controlling intestinal inflamma-
tion, and have suggested that these cells play a pivotal role
in intestinal homeostasis (2). Transfer of CD45RB
 
high
 
CD4
 
1
 
T cells from normal donors to SCID mice led to the devel-
opment of an inflammatory bowel disease (IBD)-like syn-
drome characterized by extensive mononuclear cell infil-
trates, epithelial cell hyperplasia, and ulceration (3–5).
Colitis was the result of the differential expansion of Th1
cells driven by enteric bacteria, as disease could be pre-
vented by strategies that inhibited the development of Th1
responses (6) and did not occur in T cell reconstituted mice
raised under germ-free conditions (7, 8). Importantly,
cotransfer of the reciprocal CD45RB
 
low
 
CD4
 
1
 
 subset with
an inoculum of potentially pathogenic CD45RB
 
high
 
CD4
 
1
 
cells inhibited disease. Immune suppression was dependent
on TGF-
 
b
 
 (9) and production of IL-10 (10) by T cells con-
tained within the CD45RB
 
low
 
 population. These data indi-
cate that normal mice contain a population of IL-10– and
TGF-
 
b
 
–dependent Treg cells that control inflammatory
responses in the intestine.
Subpopulations of peripheral CD4
 
1
 
 T cells have also
been shown in several different model systems to be essen-
tial for the maintenance of tolerance to tissue-specific self-
antigens (11–13). Further phenotypic characterization of
these Treg cells has shown that they express CD25, as
transfer of CD4
 
1
 
 T cells depleted of the CD25
 
1
 
 fraction to
nude mice led to the development of autoimmune gastritis
(14, 15). Furthermore, organ-specific autoimmune disease
induced by neonatal thymectomy was prevented by trans-
fer of CD25
 
1
 
CD4
 
1
 
 T cells (16). Functional analysis of
CD25
 
1
 
CD4
 
1
 
 
 
T cells in vitro showed that this population
failed to proliferate or secrete cytokines in response to
polyclonal or antigen-specific stimulation, but rather inhib-
 
Address correspondence to Fiona Powrie, Oxford University, Nuffield De-
partment of Surgery, John Radcliffe Hospital, Oxford OX3 9DU, United
Kingdom. Phone: 44-1865-221482; Fax: 44-1865-768876; E-mail:
fiona.powrie@nds.ox.ac.uk 
296
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1
 
CD4
 
1
 
 Cells
 
ited the activation of normally responsive T cells (17, 18).
Precisely how CD25
 
1
 
CD4
 
1
 
 T cells mediate immune sup-
pression in vitro has not been elucidated, but the mecha-
nism has been shown to be independent of IL-10 and
TGF-
 
b
 
 and to require cell to cell contact between re-
sponding and regulatory T cell populations.
Several factors are thought to influence the fate of T cells
after encounter with antigen, including the strength of the
signal delivered after TCR triggering, the balance of proin-
flammatory versus antiinflammatory cytokines present at
the time of T cell encounter with antigen, and the inte-
grated signals delivered by costimulatory molecules present
on the T cell surface after interaction with their ligands on
APCs (for reviews, see references 19, 20). Two well-char-
acterized costimulatory molecules are Ig superfamily mem-
bers CD28 and cytotoxic T lymphocyte–associated antigen
4 (CTLA-4), both of which interact with CD80 and CD86
present on APCs. CD28 is present on naive T cells and has
been shown to be important for the development of opti-
mal primary responses (21–23). In contrast, detectable lev-
els of CTLA-4 are induced only after T cell activation, and
its ligation results in inhibition of T cell activation. Cross-
linking of CTLA-4 concomitant with TCR signaling in-
hibits IL-2 gene expression and cell cycle progression (24,
25). The significance of signaling via CTLA-4 in vivo is re-
vealed by the fact that administration of anti–CTLA-4
mAb was able to abrogate the induction of tolerance to
specific antigens (26), enhance antitumor responses (27),
and exacerbate autoimmune reactivity (28–30). Most strik-
ingly, CTLA-4–deficient mice developed a fatal lympho-
proliferative disease and multiple organ immune pathology,
highlighting the essential role that CTLA-4 plays in the
normal homeostasis of the immune system (31, 32). Re-
cently, cross-linking of CTLA-4 in the presence of TCR
ligation has been shown to lead to TGF-
 
b
 
 secretion by pu-
rified naive CD4
 
1
 
 T cells or CD4
 
1
 
 T cell clones (33), pro-
viding an additional mechanism through which CTLA-4
may induce immune suppression.
In this study, we have further dissected the phenotype
and mechanism of action of Treg cells that control intesti-
nal inflammation. Here, we show a primary role for
CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
 cells in inhibition of colitis, and
present evidence that ligation of CTLA-4 and production
of TGF-
 
b
 
 are required for their function in vivo.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free BALB/c, C57BL/6, C57BL/
6.SJL.CD45 congenic, C57BL/6.RAG2
 
2
 
/
 
2
 
, and C.B-17 SCID
mice were maintained in the Biomedical Services Unit at the
John Radcliffe Hospital in microisolator cages with filtered air.
Mice were used at 8–12 wk of age.
 
Antibodies.
 
The following antibodies were used for cell puri-
fication: YTS169, anti–mouse CD8; TIB120, anti–mouse MHC
class II (American Type Culture Collection); M1/70, anti–mouse
Mac-1 (TIB128; American Type Culture Collection); RA3-6B2,
anti–mouse B220 (34); FITC-conjugated anti–mouse CD45RB
(clone 16A; BD PharMingen); biotinylated anti–mouse CD25
(clone 7D4; BD PharMingen); CyChrome-conjugated anti–
 
mouse CD4 (clone RM4-5; BD PharMingen); and PE-conju-
gated streptavidin (BD PharMingen). Peridinine chlorophyll pro-
tein (PerCP)-conjugated anti–mouse CD4 (clone RM4-5; BD
PharMingen), FITC-conjugated anti–mouse CD45.2 (clone 104;
BD PharMingen), and PE-conjugated anti–mouse CTLA-4
(CD152) (clone UC10-4F10-11; BD PharMingen) were used for
analysis of CTLA-4 expression. For in vivo use, anti–mouse
CTLA-4 (clone UC10-4F10-11) and anti–mouse TGF-
 
b
 
 mAb
(clone 1D11.16.8) were purified from hybridoma supernatant by
affinity chromatography, and were shown to contain 
 
,
 
1.0 en-
dotoxin unit/mg of protein. Purified hamster IgG was purchased
from Jackson Immunoresearch Laboratories.
 
Purification of T Cell Subsets.
 
CD4
 
1
 
 T cell subsets were iso-
lated from spleens as described previously (3). In brief, single cell
suspensions were depleted of CD8
 
1
 
, MHC class II
 
1
 
, Mac-1
 
1
 
,
and B220
 
1
 
 cells by negative selection using sheep anti–rat coated
Dynabeads (Dynal). The resulting CD4
 
1
 
-enriched cells were
stained with CyChrome-conjugated anti-CD4, FITC-conju-
gated anti-CD45RB, biotinylated anti-CD25 mAb, and strepta-
vidin-PE. Subpopulations of CD4
 
1
 
 cells were generated by
three-color sorting on a FACS Vantage™ (Becton Dickinson).
All populations were 
 
.
 
98.0% pure on reanalysis.
 
T Cell Reconstitution and Antibody Treatment.
 
C.B-17 SCID
mice were injected intraperitoneally with sorted CD4
 
1
 
 T cell
subpopulations in PBS. Mice received 4 
 
3
 
 10
 
5
 
 CD45RB
 
high
 
CD4
 
1
 
 cells alone or in combination with other subpopulations.
Anti–CTLA-4 mAb (200 
 
m
 
g) was injected intraperitoneally in
PBS the day after T cell reconstitution and then on alternate days
for 6 wk; mice treated with anti–TGF-
 
b
 
 mAb received 2 mg
weekly for up to 6 wk.
 
Histological Examination.
 
Colons were removed from mice 6–8
wk after T cell reconstitution and fixed in buffered 10% formalin.
6-
 
m
 
m paraffin-embedded sections were cut and stained with he-
matoxylin and eosin. Inflammation was scored in a blinded fash-
ion on a scale of 0–4, representing no change to severe changes,
as described (10).
 
Analysis of CTLA-4 Expression.
 
Lymphocyte populations
were prepared from spleen and mesenteric lymph nodes of nor-
mal and T cell–restored mice. Cells were stained with PerCP-
conjugated anti-CD4, FITC-conjugated anti-CD45.2, and PE-
conjugated anti–CTLA-4. Before staining with anti–CTLA-4
mAb, the cells were fixed with 2.0% paraformaldehyde and per-
meabilized using 0.5% saponin (Sigma-Aldrich). Samples were
analyzed on a FACSort™ using CELLQuest™ software (Becton
Dickinson).
 
Statistical Analysis.
 
Colitis scores were compared using Mann-
Whitney or Student’s 
 
t
 
 test, and differences were considered sta-
tistically significant with
 
 P 
 
, 
 
0.05.
 
Results and Discussion
 
Inhibition of Colitis Is Mediated by CD25
 
1
 
CD4
 
1
 
 T
Cells.
 
To further analyze the relationship between Treg
cells that control responses to self-antigens and those that
regulate responses driven by bacteria, CD45RB
 
low
 
CD4
 
1
 
 T
cells were sorted into CD25
 
1
 
 and CD25
 
2
 
 fractions and
tested for their ability to inhibit colitis induced by transfer
of CD45RB
 
high
 
 cells. The results clearly demonstrate that
control of intestinal inflammation resided predominantly
within the CD25
 
1
 
 fraction, as these cells significantly inhib-
ited development of colitis and wasting disease even when
transferred at a ratio of 1:8 (CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
/ 
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CD45RB
 
high
 
CD4
 
1
 
 T cells; Table I). Indeed, colons from
mice restored with a mixture of CD45RB
 
high
 
CD4
 
1
 
 and
CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
 cells exhibited no detectable
pathological changes and were indistinguishable from co-
lons from mice restored with CD45RB
 
high
 
CD4
 
1
 
 cells and
unseparated CD45RB
 
low
 
CD4
 
1
 
 cells (Fig. 1, a–d). In con-
trast, CD25
 
2
 
CD45RB
 
low
 
 cells transferred incomplete pro-
tection at the highest dose and mediated no significant reg-
ulatory function at the lower dose. Despite the fact that
CD25
 
2
 
CD45RB
 
low
 
 cells failed to efficiently prevent colitis,
 
Table I.
 
CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
 but Not CD25
 
2
 
CD45RB
 
low
 
CD4
 
1
 
 Cells Inhibit Colitis
 
Cells injected
Phenotype No. Percentage of colitis (
 
n
 
) Percentage of weight change
 
*
 
CD45RB
 
high
 
CD4
 
1
 
 alone 89 (9) 78.6 
 
6
 
 4.9
CD45RB
 
high
 
CD4
 
1
 
Plus CD45RB
 
low
 
CD4
 
1
 
2 
 
3
 
 10
 
5
 
0 (5) 103.3 
 
6
 
 1.6
Plus CD25
 
1
 
CD45RB
 
low
 
CD4
 
1
 
2 3 105 0 (4) 105.3 6 0.8
1 3 105 0 (4) 107.0 6 2.5
5 3 104 0 (5) 110.3 6 2.5
Plus CD252CD45RBlowCD41 2 3 105 38 (8) 98.5 6 5.0
5 3 105 60 (10) 86.7 6 3.5
CD251CD45RBlowCD41 alone 2 3 105 0 (3) 114.5 6 6.9
CD252CD45RBlowCD41 alone 2 3 105 0 (3) 107.0 6 0.6
SCID mice received 4 3 105 CD45RBhigh cells alone or in combination with other subpopulations as indicated. 8 wk after transfer, mice were killed
and tissues were taken for histological examination. Data are pooled from two independent experiments. CD45RBhigh versus CD45RBhigh plus
CD251CD45RBlow: P , 0.001; CD45RBhigh versus CD45RBhigh plus CD252CD45RBlow: not significant.
*Weights are expressed as a percentage of start weight 6 SEM.
Figure 1. CD41 regulatory T cells that control intestinal inflammation are CD251CD45RBlow. (a) Representative photomicrographs show severe
colitis in mice that received CD45RBhighCD41 cells alone. (b) Inhibition of colitis in mice given CD45RBhigh plus 2 3 105 unfractionated
CD45RBlowCD41 cells. (c) Regulatory T cell function is enriched within the CD251CD45RBlow subset, as 105 CD251CD45RBlow cells inhibited colitis
when transferred with CD45RBhighCD41 cells, whereas (d) mice restored with a mixture of 105 CD252CD45RBlow and CD45RBhighCD41 cells devel-
oped severe colitis. Severe colitis in mice restored with (e) CD45RBhigh and 2 3 105 CD45RBlowCD41 cells or (f) CD45RBhigh and 105
CD251CD45RBlowCD41 cells and treated with anti-CTLA-4 mAb. Mice receiving CD45RBhigh and CD45RBlowCD41 cells or CD45RBhigh and
CD251CD45RBlowCD41 cells and treated with control hamster IgG were similar to those shown in b. Original magnification: 380.298 CTLA-4–dependent Inhibition of Colitis by CD251CD41 Cells
they were also not capable of transferring the disease (Table
I), indicating that pathogenic effector cells were not present
in this population and did not account for its lack of Treg
cell function.
Signals through CTLA-4 Are Required for the Function of
Treg Cells In Vivo. These findings indicate that Treg cells
that control inflammatory responses in the intestine are en-
riched within the same phenotypic subset (CD251CD41)
as those that inhibit T cell activation in vitro and prevent
organ-specific autoimmune disease (14–16). The fact that
the function of the former, at least in vitro, requires a cog-
nate interaction between responding and regulatory popu-
lations prompted us to search for cell surface molecules that
may be involved in the function of Treg cells in vivo. A
potential candidate was CTLA-4, which has been clearly
identified as a negative regulator of T cell activation (24,
25). To analyze the role of CTLA-4 in the regulation of in-
testinal inflammation, SCID mice transferred with a mix-
ture of CD45RBhigh and CD45RBlow cells were treated
with an anti–CTLA-4 mAb or control hamster IgG. As ex-
pected, mice restored with a mixture of CD45RBhigh and
CD45RBlow cells and treated with control IgG were signif-
icantly protected from both wasting disease and colitis (Fig.
1 b and Fig. 2, a and c). In contrast, mice in the anti–
CTLA-4–treated group developed wasting disease with
identical kinetics to mice restored with CD45RBhigh cells
alone (Fig. 2, a and c). Furthermore, intestinal inflamma-
tion occurred with a similar incidence and severity in these
mice and had identical characteristics to those observed in
mice restored with CD45RBhigh cells alone, including epi-
thelial cell hyperplasia, mucin cell depletion, and pro-
nounced mononuclear cell infiltrates (Fig. 1 e and Fig. 2, a
and c). Mice lacking CTLA-4 have been shown to prefer-
entially activate Th2 responses (35); however, there was no
evidence that anti–CTLA-4 therapy induced a Th2 re-
sponse in the colon, as IFN-g and TNF-a but not IL-4 or
IL-10 mRNA were elevated in the colon of anti–CTLA-
4–treated mice with colitis (data not shown). Importantly,
anti–CTLA-4 treatment also abrogated inhibition of colitis
by CD251CD45RBlow cells, providing direct evidence that
the immune-suppressive function of CD251 Treg cells is
dependent on CTLA-4 (Fig. 1 f and Fig. 2 c).
Anti–CTLA-4 treatment may act to enhance the patho-
genicity of cells within the CD45RBhigh population. How-
ever, the kinetics of wasting disease (Fig. 2 b) as well as the
incidence and severity of colitis induced by transfer of
CD45RBhighCD41 cells was indistinguishable in anti–
CTLA-4–treated or untreated groups (Fig. 2 c). Similarly,
anti–CTLA-4 treatment did not lead to the development
of a pathogenic T cell population after transfer of
CD45RBlowCD41 T cells, as the majority of mice in this
group failed to develop wasting disease or colitis and were
not significantly different from untreated mice (Fig. 2 c).
The finding that anti–CTLA-4, which inhibits the function
of Treg cells, failed to reveal pathogenic cells among the
CD45RBlow population further supports the idea that
pathogenic effector cells are not present (at least not in a
physiologically relevant number) in the antigen-experi-
enced pool. Taken together, these data suggest that anti–
CTLA-4 acts to inhibit the function of Treg cells as op-
posed to enhancing the pathogenicity of CD45RBhigh cells
or revealing pathogenic T cells among the CD45RBlow
population.
CTLA-4 Is Expressed Predominantly on CD251CD41
Cells. The consensus of opinion on the function of
CTLA-4 is that ligation of CTLA-4 uncouples TCR liga-
Figure 2. Anti–CTLA-4 treatment abrogates the function of regulatory T cells. (a) SCID mice were reconstituted with CD45RBhighCD41 cells alone
(h) or in combination with 2 3 105 CD45RBlowCD41 cells and treated with anti–CTLA-4 mAb (d) or purified hamster IgG (s). Asterisk indicates one
of five mice killed on D32. Data represent the mean 6 SEM for five mice per group. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus
control IgG, P , 0.05. For CD45RBhigh versus CD45RBhigh plus CD45RBlow cells plus anti–CTLA-4, results were not significant (Student’s t test). (b)
SCID mice were reconstituted with CD45RBhigh cells alone and received anti–CTLA-4 mAb (j) or control hamster IgG (h). Data represent the mean 6
SEM for six mice per group. (c) SCID mice received CD45RBhighCD41 cells (h), 2 3 105 CD45RBlow cells (e), both CD45RBhighCD41 cells and 2 3
105 CD45RBlow cells (s), or CD45RBhighCD41 cells in combination with 105 CD251CD45RBlow CD41 cells (n). Mice also received either anti–
CTLA-4 (filled symbols) or control hamster IgG (open symbols). Data are pooled from three independent experiments. Significant protection was medi-
ated by CD45RBlow cells (P , 0.01) and CD251 cells (P , 0.01). Adminstration of anti–CTLA-4 mAb abrogated protection mediated by CD45RBlow
cells (P , 0.01) and CD251 cells (P , 0.05).299 Read et al. Brief Definitive Report
tion from the downstream signaling events that lead to full
T cell activation (for a review, see reference 36). However,
more recently, ligation of CTLA-4 has also been shown to
induce TGF-b secretion by both naive and effector CD41
T cells (33), suggesting that CTLA-4 may mediate positive
signaling for secretion of immune-suppressive cytokines.
Precisely how CTLA-4 is involved in the function of Treg
cells that inhibit intestinal inflammation is not known. It
may be induced on the progeny of CD45RBhighCD41 T
cells in the presence of Treg cells and serve to transmit a
negative signal to these potentially pathogenic cells. Alter-
natively, it may be present on Treg cells themselves, pro-
viding a costimulatory signal required for these cells to me-
diate their effector function. To address this issue, we have
analyzed the constitutive expression of CTLA-4 among
splenic CD41 T cell subsets. Previous studies have shown
that although CTLA-4 functions at the cell surface, it is lo-
cated primarily in endosomal vesicles, from where it has
been shown to cycle continuously to and from the cell sur-
face (37, 38). To measure both membrane and cytoplasmic
CTLA-4 expression, antibody staining was performed on
permeabilized cells. Although it has been reported that
CTLA-4 is not expressed by CD41 T cells examined di-
rectly ex vivo (39, 40), our studies revealed significant
CTLA-4 expression among CD251CD45RBlowCD41 cells
(46.4% 6 1.5; representative staining shown in Fig. 3 b)
and lower levels on the CD252 subset (12.5% 6 0.2; Fig. 3
c). Low to undetectable levels were present among
CD45RBhighCD41 cells (Fig. 3 a). These results suggest
that CTLA-4 is expressed constitutively among CD41 T
cells analyzed directly ex vivo and that this expression is re-
stricted primarily to Treg cells. Recently, expression of
CTLA-4 among CD251CD41 cells has been noted (41).
However, the significance of this was not examined.
To investigate whether inhibition of colitis by CD251
CD45RBlow cells led to induction of expression of CTLA-4
among the progeny of CD45RBhigh cells that expand in the
immunodeficient recipients, pathogenic and regulatory T
cell populations were isolated from donors congenic for
CD45 allotypes and transferred to immune-deficient recip-
ients. 4 wk after T cell reconstitution, CTLA-4 expression
on the progeny of CD45RBhighCD41 or CD251CD45RBlow
CD41 cells present in the mesenteric lymph nodes was an-
alyzed. In mice restored with CD45RBhigh cells alone,
which would normally develop colitis, CTLA-4 was ex-
pressed on a minority of cells (6.4 6 2.4%; representative
staining shown in Fig. 3 d). The picture was similar in mice
given a mixture of pathogenic and Treg cells, as under
these circumstances only 7.6 6 1.8% (representative stain-
ing shown in Fig. 3 f) of the progeny of CD45RBhighCD41
T cells expressed CTLA-4. The fact that the progeny of
CD45RBhigh cells expressed similar levels of CTLA-4
whether they were able to induce colitis (transfer of
CD45RBhigh cells alone) or when they were suppressed
(transfer of CD45RBhigh cells plus CD251 cells) argues
against the hypothesis that it is induced CTLA-4 expression
on potentially pathogenic cells in the presence of Treg cells
that accounts for the requirement for CTLA-4 in the
mechanism of immune suppression. Consistent with this,
CTLA-4 expression remained high (43.7% 6 7.8, Fig. 3 e)
on the progeny of CD251 cells as they exerted immune
suppression in vivo, providing support for the idea that it is
CTLA-4 signaling on Treg cells themselves that is crucial
for their function. As the highest levels of CTLA-4 expres-
sion were restricted to Treg cells, it was possible that anti–
CTLA-4 treatment selectively depleted these cells. How-
ever, using the congenic transfer system, it was possible to
monitor the progeny of Treg cells in mice treated with
anti–CTLA-4. Similar numbers of CD251CD41 cells were
present in anti–CTLA-4–treated mice, indicating that the
antibody did not lead to the wholesale depletion of Treg
cells (data not shown).
The Function of CD251 Treg Cells In Vivo Is Dependent on
TGF-b Production. Extensive analysis of the immune-
suppressive function of CD251 Treg cells in vitro has
shown no demonstrable role for the immune-suppressive
cytokine TGF-b (17, 18). This was somewhat at odds with
our previous observations that the ability of CD45RBlow
cells to inhibit colitis was absolutely dependent on TGF-b
(9). It is possible that this difference may reflect a compari-
son of the function of CD251 cells with unseparated
CD45RBlow cells. Given that we now show that Treg cells
Figure 3. CTLA-4 is expressed constitutively on CD251CD45RBlow
CD41 cells. (a–c) CTLA-4 staining on permeabilized (a) CD45RBhighCD41,
(b) CD251CD45RBlowCD41, and (c) CD252CD45RBlowCD41 spleno-
cytes. SSC, side scatter. (d–f) CTLA-4 expression on the progeny of (e)
CD251CD45RBlowCD41 and (d and f) CD45RBhighCD41 cells after
transfer into immunodeficient mice. C57BL/6 recombination activating
gene (RAG)22/2 mice received CD45RBhighCD41 cells from C57BL/6
mice (CD45.2) (d) alone or (e and f) in combination with 105
CD251CD45RBlowCD41 cells from C57BL/6.SJL.CD45 congenic mice
(CD45.1). 4 wk after transfer, cells from the mesenteric lymph nodes
were stained for CTLA-4 and congenic marker expression. Results are
representative of four mice (CD45RBhigh alone) and seven mice
(CD45RBhigh plus CD251) from two independent experiments.300 CTLA-4–dependent Inhibition of Colitis by CD251CD41 Cells
that most efficiently inhibit colitis are also CD251, we di-
rectly tested whether TGF-b was required for the function
of these cells in vivo. As with unseparated CD45RBlow
cells, administration of anti–TGF-b to mice usually pro-
tected from colitis by transfer of a mixture of CD45RBhigh
and CD251CD45RBlow cells led to abrogation of suppres-
sion and induction of severe colitis in the recipients (Fig.
4). These data indicate that in contrast to immune suppres-
sion in vitro, immune suppression in vivo was absolutely
dependent on TGF-b.
Data reported herein demonstrate that bacteria-driven
inflammatory responses in the intestine are regulated by the
same phenotypic subset of regulatory T cells (CD251) as
control autoimmune responses to tissue-specific self-anti-
gens (14–16) and mediate inhibition of T cell activation in
vitro (17, 18). Previous studies have failed to reveal the
mechanism of action of CD251 Treg cells, which at least in
vitro are thought to act via a cognate interaction between
responding and regulatory T cells. Our data identify both
CTLA-4 and TGF-b as essential components of the im-
mune-suppressive functions of CD251CD41 Treg cells
that control intestinal inflammation. Consistent with these
studies, Takahashi et al. (42) have reported that signaling
via CTLA-4 is also required for immune suppression in
vitro and that treatment of normal mice with anti–CTLA-4
and anti–CD25 mAbs induces autoimmune disease. The
finding that CTLA-4 plays an essential role in the function
of Treg cells that control immune responses towards intes-
tinal antigens as well as tissue specific self-antigens suggests
that similar functional subsets of Treg cells mediate these
diverse roles, emphasizing the central role that Treg cells
and CTLA-4 signaling play in the control of the immune
response.
There is now overwhelming evidence that CTLA-4 can
act as a negative regulator of T cell activation. Blockade of
CTLA-4 by injection of anti–CTLA-4 mAbs has been
shown to lead to increased T cell–mediated immunity in
several model systems, including antigen-specific responses
(26), tumor immunity (27), parasitic infection (43), and au-
toimmune disease (28–30). The consensus of opinion is
that CTLA-4 acts in a cell-autonomous fashion, and that its
expression on potentially reactive T cells results in their in-
hibition. Our observation that CTLA-4 is required for the
function of Treg cells in vivo describes a novel property of
CTLA-4, which raises the possibility that the immune
stimulatory consequences of CTLA-4 blockade may be
in part due to the inhibition of the function of Treg cells.
The findings that: (a) anti–CTLA-4 treatment abrogates the
function of Treg cells in vivo but does not enhance the
pathogenicity of CD45RBhigh cells when transferred alone;
(b) CTLA-4 is constitutively expressed by a high propor-
tion of Treg cells; and (c) potentially pathogenic T cells
whose function has been suppressed in vivo express similar
levels of CTLA-4 as uninhibited pathogenic T cells capable
of inducing colitis support the hypothesis that it is CTLA-4
expression on Treg cells themselves that is important for
their function. However, these data do not rule out the
possibility that in mixtures of pathogenic and Treg cells,
expression of CTLA-4 by the progeny of pathogenic T
cells plays a role in the mechanism of immune suppression.
The definitive answer requires transfer of T cell subsets
from CTLA-42/2 mice. However, this experimental ap-
proach is confounded by the fact that these mice die at 3–4
wk with fatal immune pathology and have highly distorted
T cell subsets (31, 32). Recently, immune pathology in-
duced in recipients after transfer of CTLA-42/2 bone mar-
row was shown to be inhibited by transfer of normal bone
marrow, indicating that CTLA-42/2 T cells can be inhib-
ited by normal T cells (44). These results, taken together
with our own, raise the possibility that costimulation of im-
mune-suppressive Treg cells as opposed to negative signal-
ing of reactive T cells accounts for some of the inhibitory
effects of CTLA-4 signaling.
Both cell contact–dependent signals (17, 18, 45) and se-
cretion of immune-suppressive cytokines (9, 10, 46) have
been shown to be involved in the function of Treg cells.
The finding that CD251 Treg cells that control intestinal
inflammation are dependent on both TGF-b and CTLA-4
suggests that a cell surface molecule that negatively regu-
lates T cell activation and secretion of immune-suppressive
cytokines may be linked and involved in the function of
the same subset of Treg cells. Cross-linking of CTLA-4 in
the presence of TCR-mediated signals has been shown to
induce TGF-b secretion, providing one possible mecha-
nism for the linkage (33). The explanation of why TGF-b
is involved in the in vivo function of Treg cells but not in
their in vitro function is not clear. Obviously, immune
suppression in vitro represents a very simplified read out of
the in vivo phenomenon, and it may be that in the latter,
TGF-b plays an important role in limiting the expansion or
homing of potentially pathogenic cells.
The results of this study identify signaling via CTLA-4 as
essential for the function of Treg cells, providing a new
mechanism by which ligation of CTLA-4 may induce im-
mune suppression. Induction of Treg cells is one of the
host’s natural mechanisms for controlling immune re-
sponses. The finding that CTLA-4 plays a nonredundant
role in the functioning of these cells will open up new ave-
nues of investigation for the development of therapeutic
strategies that seek to manipulate Treg cells.
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